HIND (35) BOLT (28) LPCN (37) BIVI (33) ⌘ Pro Terminal →

Pasithea Therapeutics Corp. (KTTA) — RQD Stock Rating Cockpit

$0.37 -5.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Pasithea Therapeutics Corp. (KTTA) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $12.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KTTA)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

34.130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE5% OF RANGE

L: $0$0.37H: $2

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on KTTA

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (43)

16/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like KTTA

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KTTA)

✓Walkthrough of KTTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KTTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -46.38%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.36H $0.39L $0.36C $0.37VOL 99.8K

RES: $0.48SUP: $0.33SMA50: $0.49SMA200: $0.63

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KTTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KTTA Butterfly Map → + Track KTTA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KTTA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KTTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KTTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KTTA)

Health Care Rank #525 of 1016 ⚔️ HIND vs KTTA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KTTA vs. HIND, BOLT, LPCN, BIVI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Pasithea Therapeutics Corp. (KTTA) ranks #525 by composite RQD confidence (44/100, grade D) and #875 by equity capitalization ($12.3M). Within this direct 5-issuer industry benchmark cohort, KTTA leads on earnings valuation at N/A trailing P/E, while KTTA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. KTTA currently leads its immediate peer cohort in composite quantitative strength at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KTTA ACTIVE Pasithea Therapeutics Corp.	D	44/100	—	—	-35.0%	-5.95%	$12.3M	Benchmark Subject
HIND Vyome Holdings Inc.	D-	35/100	—	68.4%	-35.0%	+1.74%	$12.3M	/hind-vs-ktta →
BOLT Bolt Biotherapeutics Inc.	E	28/100	—	—	-35.0%	-3.34%	$12.3M	/bolt-vs-ktta →
LPCN Lipocine Inc.	D-	37/100	—	—	-35.0%	+0.66%	$12.5M	/lpcn-vs-ktta →
BIVI BioVie Inc. (Class A)	E	33/100	—	—	-35.0%	-5.48%	$12.0M	/bivi-vs-ktta →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001841330

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pasithea Therapeutics Corp. (KTTA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$20.4M, operating cash flow of -$15.2M, and free cash flow of -$15.2M (-9.3% YoY). On the balance sheet, KTTA closed FY2025 with $60.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$20.4M	-$15.2M	-$15.2M	$60.2M	—
FY2024 (FY)	2024-12-31	$0	-$13.9M	-$13.9M	-$13.9M	$16.1M	—
FY2023 (FY)	2023-12-31	$0	-$16.0M	—	—	—	—

3. KTTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KTTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Pasithea Therapeutics Corp. (NASDAQ: KTTA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $0.37 (-5.95% 1D, market cap $12.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, KTTA ranks #525 in composite RQD confidence.

How does KTTA compare to HIND and BOLT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KTTA carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HIND (Vyome Holdings Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M) and BOLT (Bolt Biotherapeutics Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M). Among the 5-stock peer group, KTTA leads on earnings multiple (N/A) while KTTA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KTTA?

Per KTTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001841330), Pasithea Therapeutics Corp. generated $0 in revenue, -$20.4M in net income, and -$15.2M in free cash flow against $60.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KTTA trading relative to its 50-day, 200-day, and 52-week technical levels?

KTTA last traded at $0.37 (-5.95% on volume of 329,816 shares), positioning the stock -24.49% below its 50-day simple moving average ($0.49) and -41.27% below its 200-day simple moving average ($0.63). Across its 52-week range of $0.28 to $2.06, KTTA sits at the 5.1% percentile with a 14-day RSI of 34.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.42).

KTTA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell KTTA stock right now?

Pasithea Therapeutics Corp. (KTTA) currently earns a Roarable Rating of D (Sell — SELL) with 44/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is KTTA's 12-month price target and RQD AI Jury consensus?

KTTA's 12-month base price target is $0.35 (range $0.27 to $2.16), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: KTTA RQD Cockpit KTTA 12M Forecast KTTA Earnings & Move KTTA Dividends & DRIP KTTA Insiders & 13F KTTA Whale Options KTTA Profit Sankey KTTA News & Why